The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 296.00
Bid: 295.00
Ask: 299.00
Change: 0.00 (0.00%)
Spread: 4.00 (1.356%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 296.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS REPORTS: Elementis swings to profit; Hutchmed changes CEO

Thu, 03rd Mar 2022 13:02

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Elementis PLC - London-based speciality chemicals - Swings to profit in 2021, with pretax profit of USD5.8 million, up from a loss of USD68.8 million in 2020. Strong new business momentum, targeted pricing actions and volume recovery boost revenue by 17% in the year to USD880 million from USD751 million the year before. Dividends may be reinstated in the medium term, but remain suspended. For 2022, global supply chain issues and cost inflation are a concern, but it is off to "an encouraging start".

----------

Synthomer PLC - Essex-based chemicals company - Profit before tax rockets in 2021 to GBP283.9 million from GBP20.3 million in 2020, as revenue is up 42% to GBP2.33 billion from GBP1.64 billion. Underlying pretax profit more than doubles to GBP420.1 million from GBP160.0 million. Profit is being used to make "major inorganic and organic investments" to support further growth. In 2022 so far, nitrile latex demand is "subdued" as Covid eases and inventories of medical gloves are high, while all other divisions have started 2022 well. Final dividend is 21.3 pence, over double that of 8.3p in 2020, for a total in 2021 of 30.0p, up from 11.6p the prior year.

----------

Glanbia PLC - Kilkenny, Ireland-based nutrition company - Revenue comes in ahead of expectations for 2021 at EUR4.20 billion, up 9.8% from EUR3.82 billion in 2020. Profit before tax rises 21% to EUR158.0 million from EUR131.1 million. Says performance was driven by strong global consumer demand. A final dividend of 17.53 cents is proposed, bringing the year's total to 29.28 cents, up 10% on 2020, and launches new EUR50 million share buyback. Growth in revenue is expected for 2022, and says inflationary costs will be managed with higher sales prices.

----------

Galliford Try Holdings PLC - Uxbridge, England-based construction company - Pretax profit up to GBP7.1 million in first half ended December 31 from GBP4.1 million a year before. Revenue is up 10% to GBP594 million from GBP542 million in the prior year. Order book is up to GBP3.4 billion from GBP3.3 billion a year ago. The company boosts interim dividend by 83% to 2.2 pence from 1.2p the year before. Outlook for the rest of the year is positive, with 95% of projected revenue already secured.

----------

Empiric Student Property PLC - London-based owner and operator of student accommodation - Swings to profit in 2021, with a pretax profit of GBP29.2 million from a pretax loss of GBP24.0 million. Net rental inome drops 11% year-on-year to GBP32.9 million from GBP32.9 million, with total revenue down 6% to GBP56.0 million from GBP59.4 million. Dividends resume in fourth quarter, with payment of 2.5p, and targets fully covered and progressive dividends going forward, to increase as occupancy rates normalise. For the academic year starting in 2022, Empiric expects to come in at the top of its 85% to 95% target occupancy rate.

----------

Hutchmed (China) Ltd - Hong Kong-based biopharmaceutical company - Total revenue for 2021 is USD356.1 million up 56% year-on-year from USD228.0 million. Loss before tax of USD215.7 million widens from USD189.7 million in FY20. Momentum is continuing into 2022, and it held over USD1 billion in cash on December 31. Christian Hogg retires as chief executive officer, after 22 years with the company and 15 years as CEO. Promotes Chief Scientific Officer Weiguo Su, a 17-year company veteran, to CEO. The changes are effective from Friday.

----------

AIB Group PLC - Dublin-based bank - Swings to pretax profit of EUR629 million in 2021 from a loss of EUR931 million. Net interest income drops 4% to EUR1.79 billion from EUR1.87 billion the prior year. Gross loans were down 2% to EUR56.5 billion from EUR59.4 billion. Recommends dividend of 4.5 pence per share for the year, with no dividend having been paid in 2021. AIB expects net interest income to be "stable" in 2022.

----------

Hunting PLC - London-based energy services - In 2021, revenue drops 17% to USD521.6 million from USD626.0 million in 2020, but pretax loss from operations narrows to USD85.5 million from USD223.0 million. Second half of 2021 lifted by improved trading and recovering commodity prices, after first half hit by global reduction in activity in oil & gas. A final dividend of 4.0 cents will be paid out for the year, unchanged from 2020. As Covid-related operational issues ease in its first quarter, it predicts a "much improved" 2022.

----------

By Elizabeth Winter; elizabethwinter@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
26 May 2023 08:56

Hutchmed China celebrates FDA review, teases new data at ASCO meeting

(Alliance News) - Hutchmed China Ltd on Friday celebrated a priority review granted by the US FDA for its cancer drug fruquintinib, and promised to present new data for this and two other therapies at the American Society of Clinical Oncology next month.

Read more
5 May 2023 15:57

UK shareholder meetings calendar - next 7 days

Monday 8 May 
no events scheduled 
Tuesday 9 May 
Caledonia Mining Corp PLCAGM
Direct Line Insurance Group PLCAGM
Foxtons Group PLCAGM
Hostelworld Group PLCAGM
IWG PLCAGM
Just Group PLCAGM
Midwich Group PLCAGM
Osirium Technologies PLCAGM
Windward LtdAGM
Wednesday 10 May 
abrdn PLCAGM
Antofagasta PLCAGM
Cenkos Securities PLCAGM
Ecora Resources PLCAGM
H&T Group PLCAGM
Harbour Energy PLCAGM
Jupiter Fund Management PLCAGM
Literacy Capital PLCAGM
Luceco PLCAGM
Marshalls PLCAGM
National Express Group PLCAGM
Renewables Infrastructure Group LtdAGM
Rentokil Initial PLCAGM
Seplat Energy PLCAGM
Spirax-Sarco Engineering PLCAGM
TClarke PLCAGM
Thursday 11 May 
88 Energy LtdAGM
Cairn Homes PLCAGM
Capita PLCAGM
Clarkson PLCAGM
Costain Group PLCAGM
Eleco PLCAGM
Eurocell PLCAGM
FBD Holdings PLCAGM
Genedrive PLCGM re Equity Prepayment Facility
Genel Energy PLCAGM
Gresham House PLCAGM
Gym Group PLCAGM
Hiscox LtdAGM
Irish Continental Group PLCAGM
John Wood Group PLCAGM
MyHealthChecked PLCAGM
OSB Group PLCAGM
Poolbeg Pharma PLCAGM
Rolls-Royce Holdings PLCAGM
Serinus Energy PLCAGM
Uniphar PLCAGM
Videndum PLCAGM
WAG Payment Solutions PLCAGM
Friday 12 May 
Balfour Beatty PLCAGM
Derwent London PLCAGM
Goodbody Health LtdAGM
GreenRoc Mining PLCAGM
Hutchmed (China) LtdAGM
Itim Group PLCAGM
Itsarm PLCGM re delisting from AIM
Wheaton Precious Metals CorpAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
18 Apr 2023 12:30

Hutchmed's gastric cancer treatment accepted for review in China

(Sharecast News) - Hutchmed China announced on Tuesday that its new drug application (NDA) for fruquintinib, in combination with paclitaxel has been accepted for review by the National Medical Products Administration (NMPA) in China.

Read more
18 Apr 2023 09:55

Hutchmed gets Chinese approval for fruquintinib new drug application

(Alliance News) - Hutchmed (China) Ltd on Tuesday said the China National Medical Products Administration accepted its new drug application for fruquintinib in combination with paclitaxel.

Read more
4 Apr 2023 13:56

Hutchmed to start registration phase enrolments for two treatments

(Alliance News) - Hutchmed China Ltd on Tuesday said it will start registration phase enrolments for two of its prospective treatments under study, HMPL-453 and savolitinib.

Read more
31 Mar 2023 13:47

Hutchmed completes rolling FDA submission for colorectal cancer drug

(Sharecast News) - Pharmaceuticals developer Hutchmed China announced the completion of its rolling submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for its oral inhibitor 'fruquintinib'.

Read more
31 Mar 2023 12:15

Hutchmed submits new drug application to US FDA for cancer treatment

(Alliance News) - Hutchmed (China) Ltd on Friday said it has completed the rolling submission of a new drug application for its fruquintinib cancer drug to the US Food & Drug Administration.

Read more
14 Mar 2023 14:23

Hutchmed China inks global licensing deal with Takeda on fruquintinib

(Alliance News) - Hutchmed China Ltd on Tuesday said it closed a license agreement with a subsidiary of Tokyo-based drug maker Takeda Pharmaceutical Co Ltd for fruquintinib.

Read more
8 Mar 2023 14:07

DIRECTOR DEALINGS: Hutchmed CFO banks GBP4 million; Haleon chair buys

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Tuesday and Wednesday and not separately reported by Alliance News:

Read more
28 Feb 2023 11:43

Hutchmed expects revenue climb from oncology, immunology division

(Alliance News) - Hutchmed (China) Ltd expects a sharp rise in revenue from its oncology and immunology-focused arm, as the biopharmaceutical firm looks forward to a productive 2023.

Read more
27 Feb 2023 11:39

Hutchmed enrols last patient in lymphoma treatment trial

(Sharecast News) - Hutchmed China announced the completion of patient enrollment in a phase two registration trial of 'amdizalisib' on Monday, for the treatment of relapsed or refractory follicular lymphoma (FL), which is a subtype of non-Hodgkin's lymphoma.

Read more
27 Feb 2023 11:11

Hutchmed completes patient enrolment for trial testing cancer therapy

(Alliance News) - Hutchmed (China) Ltd on Monday said that it has completed patient enrolment for the Phase Two registration trial of amdizalisib, its once-a-day oral monotherapy in patients with relapsed or refractory follicular lymphoma.

Read more
21 Feb 2023 15:49

UK earnings, trading statements calendar - next 7 days

Wednesday 22 February 
Avingtrans PLCHalf Year Results
City of London Investment Group PLCHalf Year Results
Conduit Holdings LtdFull Year Results
Hochschild Mining PLCFull Year Results (TBC)
Liberty Global PLCFull Year Results
Lloyds Banking Group PLCFull Year Results
Primary Health Properties PLCFull Year Results
Renewables Infrastructure Group LtdFull Year Results
Rio Tinto PLCFull Year Results
Synectics PLCFull Year Results
TBC Bank Group PLCFull Year Results
Transense Technologies PLCHalf Year Results
Thursday 23 February 
Anglo American PLCFull Year Results
Arbuthnot Banking Group PLCTrading Statement
BAE Systems PLCFull Year Results
Drax Group PLCFull Year Results
Driver Group PLCFull Year Results
Genus PLCHalf Year Results
Greencoat UK Wind PLCFull Year Results (TBC)
Harmony Energy Income Trust PLCFull Year Results
Hays PLCHalf Year Results
Hikma Pharmaceuticals PLCFull Year Results
Howden Joinery Group PLCFull Year Results
Macfarlane Group PLCFull Year Results
Made Tech Group PLCHalf Year Results
Mondi PLCFull Year Results
Morgan Sindall Group PLCFull Year Results
Pantheon International PLCHalf Year Results
Rolls-Royce Holdings PLCFull Year Results
Serco Group PLCFull Year Results
Spectris PLCFull Year Results
Versarien PLCFull Year Results
WPP PLCFull Year Results
Friday 24 February 
ASA International Group PLCTrading Statement
CVS Group PLCHalf Year Results
European Opportunities Trust PLCHalf Year Results
Grit Real Estate Income Group LtdHalf Year Results
Irish Residential Properties REIT PLCFull Year Results
International Consolidated Airlines Group SAFull Year Results
Jupiter Fund Management PLCFull Year Results
Monday 27 February 
Associated British Foods PLCTrading Statement
Beeks Financial Cloud Group PLCHalf Year Results
Bunzl PLCFull Year Results
Centralnic Group PLCFull Year Results
Dechra Pharmaceuticals PLCHalf Year Results
DX Group PLCHalf Year Results
GlobalData PLCFull Year Results
Greencoat Renewables PLCFull Year Results
Kosmos Energy LtdFull Year Results
Quartix Technologies PLCFull Year Results
RHI Magnesita NVFull Year Results
Senior PLCFull Year Results
Tuesday 28 February 
abrdn PLCFull Year Results
Benchmark Holdings PLCQ1 Results
Bluefield Solar Income Fund LtdHalf Year Results
boohoo Group PLCFull Year Results
Cap-XX LtdHalf Year Results
Croda International PLCFull Year Results
Dalata Hotel Group PLCFull Year Results
Derwent London PLCFull Year Results
Hutchmed (China) LtdFull Year Results
Intertek Group PLCFull Year Results
Kitwave Group PLCFull Year Results
Man Group PLCFull Year Results
McBride PLCHalf Year Results
Morgan Advanced Materials PLCFull Year Results
Ocado Group PLCFull Year Results
Princess Private Equity Holding LtdFull Year Results
Rotork PLCFull Year Results
St James's Place PLCFull Year Results
S-Ventures PLCFull Year Results
Travis Perkins PLCFull Year Results
Uniphar PLCFull Year Results
Unite Group PLCFull Year Results
Videndum PLCFull Year Results
XP Power LtdFull Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
23 Jan 2023 09:01

Hutchmed signs drug licensing deal with Takeda for sales outside China

(Alliance News) - Hutchmed (China) Ltd on Monday said it has signed an licensing agreement with Takeda Pharmaceutical Co Ltd for the Japanese company to commercialise Hutchmed's key cancer drug outside China.

Read more
18 Jan 2023 19:03

TRADING UPDATES: Galileo confirms gold zone; Spectral hails results

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.